This is a retrospective, descriptive study with longitudinal follow-up aimed at evaluating the clinical, paraclinical characteristics and survival of gemcitabine-carboplatin regimen chemotherapy of recurrent or metastatic in triple negative breast cancer at National Cancer Hospitalfrom January 2014 to December 2021.